Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07011797 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants
A Phase 2 study of Obesity, sponsored by Corxel Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
- 17
- Study locations
NCT07011797: Active Phase 2 study of Obesity, sponsored by Corxel Pharmaceuticals.
NCT07011797 is a Phase 2 study of Obesity that is active but no longer recruiting, run by Corxel Pharmaceuticals. The registered enrollment target is 250 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (69% lower). The trial reports 17 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07011797, a Phase 2 study of Obesity, is active but no longer recruiting, sponsored by Corxel Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study: * To evaluate the efficacy of different dose levels of CX11 tablets in body weight reduction as compared to placebo. * To compare the changes of effects in weight and weight-related indicators at the visit time points. * To evaluate the tolerability and safety of different doses of CX11 tablets in overweight/obese participants. * To assess the pharmacokinetics (PK) of different doses of CX11 tablets in overweight/obese participants. Overweight/obese participants who are successfully screened will be randomized in a 1:1:1:1:1 ratio to different doses of CX11 tablets or placebo. All participants will enter a 2-week follow-up period after 36 weeks of treatment for safety observation.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG CX11
Study Locations (17)
Florida
- Angels Clinical Research Institute - Miami - Doral
- AES - DRS - Optimal Research Florida - Melbourne - Melbourne
- Angels Clinical Research Institute - Miami
- Palm Springs Community Health Center - Miami Lakes
- Oceanic Research Group, LLC - North Miami Beach
Texas
- Velocity Clinical Research - Dallas - PPDS - Dallas
- Epic Clinical Research - Alliance Clinical - Lewisville - Lewisville
- AES - DRS - Synexus Clinical Research US, Inc. - San Antonio - San Antonio
- Flourish Research - San Antonio - PPDS - San Antonio
California
- 310 Clinical Research - Alliance Clinical - Los Angeles - Inglewood
- Acclaim Clinical Research - Alliance Clinical - San Diego - San Diego
Georgia
- Privia Medical Group Georgia, LLC - Savannah - Javara - PPDS - Savannah
- Privia Medical Group Georgia, LLC - Thomasville - Javara - PPDS - Thomasville
Arizona
- AES - DRS - Synexus Clinical Research US, Inc. - Phoenix Central - Phoenix
Indiana
- Velocity Clinical Research - Valparaiso (Buynak Clinical Research) - PPDS - Valparaiso
Minnesota
- Mankato Clinic - East Main Street - Javara - PPDS - Mankato
Ohio
- Velocity Clinical Research - Cincinnati (Springdale) - Ohio - PPDS - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2025-06-17 |
| Est. Completion | 2026-04-06 |
| Phase | Phase 2 |
What the registry record for NCT07011797 still lists
NCT07011797 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (69% lower).
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07011797 lists 17 locations in 8 states (Florida, Texas, California).
Frequently Asked Questions
What is clinical trial NCT07011797 about?
NCT07011797 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants". This is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study: * To evaluate the efficacy of different dose levels of CX11 tablets in body weight reduction as compared to placebo. * To compare the changes of effects in weight and weight-related indicators at the visit t...
What is the current status of trial NCT07011797?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2025-06-17. Estimated completion is 2026-04-06.
What conditions does trial NCT07011797 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT07011797?
The interventions under investigation include: Placebo (OTHER), CX11 (DRUG).
Who is sponsoring clinical trial NCT07011797?
This trial is sponsored by Corxel Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07011797 being conducted?
This trial has 17 study locations across Arizona, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07011797's enrollment target sits among peer trials
250 255th of 1053 higher than 789 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI